Oncolytics Biotech Inc. Completes Move From Alberta To Nevada, Establishes U.S. Headquarters In San Diego

Oncolytics Biotech Inc., a clinical-stage immunotherapy company advancing the development of its lead candidate, pelareorep, announced the completion of its previously planned change in the jurisdiction of incorporation. The company has transitioned from being incorporated in the Province of Alberta, Canada, to being incorporated in the State of Nevada in the United States. This change, referred to as the Domestication, was carried out through a series of steps, beginning with the continuation of the company from Alberta to the Province of British Columbia on March 17, 2026. While Oncolytics will maintain its existing office in Calgary, the company’s San Diego location will now serve as its headquarters.

Shareholders approved the Domestication during a Special Meeting of Shareholders held on January 15, 2026. The process was completed on March 31, 2026, following the submission and approval of required filings by the Nevada Secretary of State. Oncolytics’ common stock will continue trading on The Nasdaq Stock Market LLC under the ticker symbol ONCY. As of today, the company’s new CUSIP number is 68237V 103, and its ISIN is US68237V1035.

According to the company, the majority of its investors, leadership team, and capital markets activities are now based in the United States. As a result, transitioning to a U.S. jurisdiction is expected to offer several advantages, including improved operational efficiency, a more streamlined regulatory framework, and strengthened access to U.S. capital markets.

Chief Executive Officer Jared Kelly stated that Nevada’s corporate legal environment offers potential benefits for biotechnology companies, particularly for organizations seeking to enhance operational efficiency. He explained that because Oncolytics no longer met the criteria to be considered a foreign private issuer under U.S. securities regulations, updating the company’s corporate structure was a logical step. He added that while clinical data and regulatory progress remain the core drivers of long-term value, the shift to a U.S. incorporation is expected to support the company’s ability to execute more efficiently as it pursues its strategic objectives.